R&D | November 25, 2025
Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025
Jaypirca is making waves in the fight against B-cell malignancies
Jaypirca is making waves in the fight against B-cell malignancies
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
It is developing the drug candidate to potentially treat immunological diseases
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Phase 3 study results will form the basis for future discussions with global regulatory authorities
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated
